RPRX Form 4: Director Bonnie Bassler Acquires 1,047 Shares at $35.79

Bonnie L. Bassler, a director of Royalty Pharma plc (RPRX), reported a change in beneficial ownership on 09/30/2025.

Rhea-AI Filing Summary

Bonnie L. Bassler, a director of Royalty Pharma plc (RPRX), reported a change in beneficial ownership on 09/30/2025. The Form 4 shows an acquisition of 1,047 Class A ordinary shares at a reported price of $35.7872 per share, described as shares issued under the company's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. The filing lists 72,165 shares as the amount of securities beneficially owned following the reported transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Bassler.

Positive

• Director alignment with shareholders: Award received under the 2020 Independent Director Equity Incentive Plan, tying compensation to company equity
• Transparent disclosure: Form 4 specifies the grant amount (1,047 shares), price ($35.7872), and that it substituted a $37,500 quarterly retainer

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director equity award reported; small granted amount relative to typical institutional holdings, likely immaterial to company valuation.

The filing documents a non-derivative acquisition of 1,047 Class A ordinary shares by Director Bonnie L. Bassler under the issuer's director equity plan, received in lieu of a $37,500 quarterly retainer. The transaction price is shown as $35.7872 per share and the post-transaction beneficial ownership is reported as 72,165 shares. This is a standard compensation-related issuance to a director rather than an open-market purchase or sale and does not indicate active trading or a change in control. Materiality appears limited based on the nature and size of the grant.

Corporate Governance Expert

TL;DR: Typical director compensation disclosure; reflects equity-based retainer, consistent with governance best practices for alignment.

The Form 4 discloses shares issued under the 2020 Independent Director Equity Incentive Plan as compensation for board service. Receiving shares in lieu of cash retainers is a common governance practice to align director interests with shareholders. The report was executed by an attorney-in-fact and includes an explicit explanatory remark about the award. No departures, resignations, or other governance events are disclosed in this filing.

Insider Trade Summary

Grant/Award: 1,047 shares

Grant/Award 1 txn

Insider Bassler Bonnie L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	1,047	$35.7872	$37K

Holdings After Transaction: Class A Ordinary Shares — 72,165 shares (Direct)

Footnotes (1)

1. F1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bonnie L. Bassler report on Form 4 for RPRX?

She reported acquiring 1,047 Class A ordinary shares on 09/30/2025 at a reported price of $35.7872 per share under the company's director equity plan.

Why were the shares issued to the reporting person?

The shares were issued in lieu of a quarterly retainer payment of $37,500 under Royalty Pharma's 2020 Independent Director Equity Incentive Plan.

How many shares does Bonnie L. Bassler beneficially own after the transaction?

The Form 4 reports 72,165 shares as the amount of securities beneficially owned following the reported transaction.

When was the transaction dated on the Form 4?

The transaction date shown is 09/30/2025 and the filing was signed on that date by an attorney-in-fact.

Was this a market purchase or a compensation issuance?

The filing states the shares were issued under the 2020 Independent Director Equity Incentive Plan in lieu of a cash retainer, indicating a compensation issuance rather than an open-market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/30/2025 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bassler Bonnie L

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	09/30/2025		A		1,047	A	$35.7872(1)	72,165	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Bonnie L. Bassler	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.